[ad_1]
As part of its advice on safety-related aspects to European
Medicines Agency committees stemming from its June 7-10 meetings,
the Pharmacovigilance Risk Assessment Committee
(PRAC) discussed direct healthcare professional
communications (DHPCs) containing important information for
Neofordex (dexamethasone) and Xalkori (crizotinib).
Xalkori: Vision disorders, including risk of severe
visual loss, need for monitoring in pediatric patients
This…
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Try before you buy
• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
• Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
• Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
• Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
• Daily roundup of key events in pharma and biotech.
• Monthly in-depth briefings on Boardroom appointments and M&A news.
• Choose from a cost-effective annual package or a flexible monthly subscription.
[ad_2]
Source link
